These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12869459)

  • 1. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.
    Wrenger E; Müller R; Moesenthin M; Welte T; Frölich JC; Neumann KH
    BMJ; 2003 Jul; 327(7407):147-9. PubMed ID: 12869459
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
    Erden I; Yalcin S; Ozhan H
    Kardiol Pol; 2010 Sep; 68(9):1043-5; discussion 1046. PubMed ID: 20859899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
    Fujii H; Nakahama H; Yoshihara F; Nakamura S; Inenaga T; Kawano Y
    Kobe J Med Sci; 2005; 51(1-2):1-6. PubMed ID: 16199929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure. A retrospective analysis of 125 consecutive cases].
    Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
    Ugeskr Laeger; 2004 Sep; 166(37):3201-3. PubMed ID: 15384373
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug-related hyperkalemia resulted from spironolactone and angiotensin converting enzyme inhibitors therapy].
    Dutka M; Dzielski T; Wojciechowska J; Heller L; Trybus M
    Pol Merkur Lekarski; 1999 Aug; 7(38):69-70. PubMed ID: 10522422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
    Abbas S; Ihle P; Harder S; Schubert I
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):406-13. PubMed ID: 25683504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An elderly man with known heart failure admitted with cardiogenic shock].
    Hovland A; Fagerheim AK; Hardersen R; Nielsen EW
    Tidsskr Nor Laegeforen; 2010 Jul; 130(13):1352-4. PubMed ID: 20596117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug safety in patients with heart failure.
    Juurlink DN; Hansten PD
    Arch Intern Med; 2005 Jan; 165(1):118. PubMed ID: 15642888
    [No Abstract]   [Full Text] [Related]  

  • 11. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age.
    Dinsdale C; Wani M; Steward J; O'Mahony MS
    Age Ageing; 2005 Jul; 34(4):395-8. PubMed ID: 15955761
    [No Abstract]   [Full Text] [Related]  

  • 13. [Late drug-induced hyperkalemia in a patient with congestive heart failure].
    Konopa J; Bułło B; Rutkowski B
    Przegl Lek; 2005; 62(7):732-3. PubMed ID: 16463712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
    N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrocardiogram changes in hyperkalemia: there and back again.
    Zimlichman E; Liran O
    Isr Med Assoc J; 2005 Nov; 7(11):748. PubMed ID: 16309005
    [No Abstract]   [Full Text] [Related]  

  • 16. Study warns of danger of combining spironolactone and ACE inhibitors in heart patients.
    Gottlieb S
    BMJ; 2004 Aug; 329(7463):420. PubMed ID: 15321896
    [No Abstract]   [Full Text] [Related]  

  • 17. Spironolactone + ace inhibitor or sartan: risk of hyperkalaemia.
    Prescrire Int; 2004 Apr; 13(70):58. PubMed ID: 15148978
    [No Abstract]   [Full Text] [Related]  

  • 18. Elderly heart failure patients with drug-induced serious hyperkalemia.
    Vanpee D; Swine CH
    Aging (Milano); 2000 Aug; 12(4):315-9. PubMed ID: 11073352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.